NORFOLK, Va., Feb. 15, 2017 -- Beaufort, a contract research organization (CRO) and consultancy, has obtained ISO 9001:2015 certification. The certification demonstrates that Beaufort provides consistently good quality services to the life sciences industry in its clinical research, regulatory affairs, quality, and staffing solutions.
“We are proud that Beaufort is one of very few CROs to obtain ISO certification,” said Beaufort President Clay Gill. “This certification reflects Beaufort’s rigorous dedication to meeting client requirements, upholding the highest quality standards, and continuously improving processes throughout our organization.”
Gill continued, “Sponsors can be confident that their projects will be conducted with the highest quality management principles and process-driven methodologies.”
ISO (International Organization for Standardization) is an independent, non-governmental worldwide federation that develops international standards. ISO 9001:2015, the latest edition of ISO’s flagship quality management systems standard, is a worldwide quality standard that helps organizations demonstrate that they offer products and services of consistently good quality.
“We believe a well-structured quality system is critical to the success of our clients’ work. This ISO certification provides third party validation of our commitment to a quality-first approach and helps further set Beaufort apart from other CROs,” explained John R. Wilson Jr., PhD, MPH, Beaufort senior vice president of clinical development and quality solutions.
To obtain ISO 9001:2015 certification, a firm must demonstrate that it: practices evidence-based decision making; addresses risks and opportunities in a methodical manner; and ensures that quality policy and quality objectives are established for the quality management system that are compatible with the context and strategic direction of the organization.
Beaufort’s independent assessment and certification was performed by accredited registrar Integrated Management Systems Group (IMSG).
About Beaufort, LLC
Beaufort, LLC, is a contract research organization that provides in vitro diagnostic, medical device and biopharmaceutical clinical and regulatory services, and a full range of quality solutions and staffing solutions. For more than a decade, companies worldwide have trusted Beaufort for its client-oriented approach to research. With operations spanning the globe, Beaufort has a proven track record working closely with clients and regulatory agencies internationally to bring complex and therapeutic-specific products to market. Learn more at www.BeaufortCRO.com.
Jennifer Petit (757) 656-9763 [email protected]


Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Instagram Outage Disrupts Thousands of U.S. Users
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 



